Arnicare Leg Cramps

Arnica Montana, Lactic Acid, L-, Zinc Oxide


Boiron
Human Otc Drug
NDC 0220-9073
Arnicare Leg Cramps also known as Arnica Montana, Lactic Acid, L-, Zinc Oxide is a human otc drug labeled by 'Boiron'. National Drug Code (NDC) number for Arnicare Leg Cramps is 0220-9073. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Arnicare Leg Cramps drug includes Arnica Montana - 9 [hp_C]/1 Lactic Acid, L- - 3 [hp_C]/1 Zinc Oxide - 3 [hp_C]/1 . The currest status of Arnicare Leg Cramps drug is Active.

Drug Information:

Drug NDC: 0220-9073
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Arnicare Leg Cramps
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Arnica Montana, Lactic Acid, L-, Zinc Oxide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Boiron
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ARNICA MONTANA - 9 [hp_C]/1
LACTIC ACID, L- - 3 [hp_C]/1
ZINC OXIDE - 3 [hp_C]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 15 Jun, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 15 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Boiron
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:O80TY208ZW
F9S9FFU82N
SOI2LOH54Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0220-9073-0611 TABLET in 1 TUBE (0220-9073-06)15 Jun, 2018N/ANo
0220-9073-9033 TUBE in 1 PACKAGE (0220-9073-90) / 11 TABLET in 1 TUBE15 Jun, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose* arnica montana 9c hpus relieves muscle fatigue causing or caused by cramps sarcolacticum acidum 3c hpus relieves pain and stiffness from muscular overexertion zincum oxydatum 3c relieves day and night muscle cramps

Product Elements:

Arnicare leg cramps arnica montana, lactic acid, l-, zinc oxide water arnica montana arnica montana zinc oxide zinc oxide citric acid monohydrate magnesium stearate lactic acid, l- lactic acid, l- dextrose monohydrate lemon lactose, unspecified form anhydrous lactose none

Indications and Usage:

Uses* temporarily relieves day and night cramps and spasms in calves, legs, thighs, and arms and cramps from muscular overexertion.

Warnings:


Dosage and Administration:

Directions adults and children 12 years of age and older: at the onset of symptoms, chew or allow 1 tablet to dissolve in the mouth, up to 6 times per day. for exercise-induced cramps and spasms, take before, during, and after activity. contains dextrose; consider rinsing mouth with water if taken at bedtime. children under 12 years of age: not recommended.

Stop Use:

Stop use and ask a doctor if symptoms persist for more than 3 days or worsen, new symptoms occur, or if redness or swelling is present. these could be signs of a serious condition.

Package Label Principal Display Panel:

Label label box tube

Further Questions:

Quesions or comments? arnicare.com boironusa.com info@boiron.com 1-800-boiron-1 (1-800-264-7661) made in france distributed by: boiron inc. newtown square, pa 19073-3267


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.